Padmasini Kumar

2.0k total citations
27 papers, 1.3k citations indexed

About

Padmasini Kumar is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Padmasini Kumar has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Immunology and 9 papers in Oncology. Recurrent topics in Padmasini Kumar's work include Cancer Research and Treatments (8 papers), Immunotherapy and Immune Responses (8 papers) and RNA Interference and Gene Delivery (7 papers). Padmasini Kumar is often cited by papers focused on Cancer Research and Treatments (8 papers), Immunotherapy and Immune Responses (8 papers) and RNA Interference and Gene Delivery (7 papers). Padmasini Kumar collaborates with scholars based in United States. Padmasini Kumar's co-authors include Thomas E. Van Dyke, Christopher W. Cutler, Mansour Mohamadzadeh, Jacques Banchereau, Bali Pulendran, H. Anne Pereira, Neil Senzer, John Nemunaitis, Beena O. Pappen and Phillip B. Maples and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Padmasini Kumar

27 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Padmasini Kumar United States 16 717 516 492 143 137 27 1.3k
Jonathan Chang United States 10 700 1.0× 332 0.6× 349 0.7× 109 0.8× 132 1.0× 13 1.3k
Inbal Mishalian Israel 18 1.7k 2.4× 463 0.9× 867 1.8× 113 0.8× 158 1.2× 26 2.4k
Roberto Carrió United States 18 1.1k 1.5× 819 1.6× 340 0.7× 62 0.4× 252 1.8× 27 1.8k
Mariette Mohaupt Germany 8 1.3k 1.8× 450 0.9× 470 1.0× 48 0.3× 99 0.7× 8 1.8k
Amanda Guth United States 19 799 1.1× 322 0.6× 284 0.6× 377 2.6× 66 0.5× 37 1.3k
Federica Pericle United States 27 1.2k 1.7× 557 1.1× 595 1.2× 133 0.9× 101 0.7× 42 1.9k
Connor J. Dwyer United States 13 536 0.7× 256 0.5× 463 0.9× 70 0.5× 77 0.6× 25 1.0k
Lucia Schwarzfischer Germany 14 795 1.1× 842 1.6× 199 0.4× 89 0.6× 205 1.5× 15 1.6k
Anthony Marinov United States 16 580 0.8× 509 1.0× 138 0.3× 140 1.0× 130 0.9× 21 1.4k
Masaaki Hashiguchi Japan 21 1.3k 1.8× 300 0.6× 553 1.1× 70 0.5× 65 0.5× 43 1.8k

Countries citing papers authored by Padmasini Kumar

Since Specialization
Citations

This map shows the geographic impact of Padmasini Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Padmasini Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Padmasini Kumar more than expected).

Fields of papers citing papers by Padmasini Kumar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Padmasini Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Padmasini Kumar. The network helps show where Padmasini Kumar may publish in the future.

Co-authorship network of co-authors of Padmasini Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Padmasini Kumar. A scholar is included among the top collaborators of Padmasini Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Padmasini Kumar. Padmasini Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Manning, Luisa, Minal Barve, Gladice Wallraven, et al.. (2017). Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors. 2(1). 3 indexed citations
3.
Rao, Donald D., Zhaohui Wang, Xiuquan Luo, et al.. (2016). Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Molecular Therapy. 24(8). 1412–1422. 37 indexed citations
4.
Wang, Zhaohui, et al.. (2016). Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery. Toxicological Sciences. 155(2). 400–408. 7 indexed citations
5.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Molecular Therapy. 23(6). 1103–1109. 48 indexed citations
6.
Barve, Minal, Zhaohui Wang, Padmasini Kumar, et al.. (2015). Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer. Molecular Therapy. 23(6). 1123–1130. 14 indexed citations
7.
Wu, James X., Jiyang Yu, Guisheng Zhou, et al.. (2014). Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Cancer Gene Therapy. 21(2). 48–53. 16 indexed citations
8.
Nemunaitis, John, Minal Barve, Douglas Orr, et al.. (2014). Summary of bi-shRNA<sup>furin</sup>/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver. Oncology. 87(1). 21–29. 41 indexed citations
9.
Nemunaitis, John, Neil Senzer, Padmasini Kumar, et al.. (2013). Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine. Gene Therapy. 20(9). 875–879. 7 indexed citations
10.
Rao, Donald D., Neil Senzer, Zhaohui Wang, et al.. (2012). Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application. Methods in molecular biology. 942. 259–278. 15 indexed citations
11.
Maples, Phillip B., Padmasini Kumar, Yang Yu, et al.. (2010). FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin. BioProcessing Journal. 8(4). 4–14. 24 indexed citations
12.
Rao, Donald D., Phillip B. Maples, Neil Senzer, et al.. (2010). Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Therapy. 17(11). 780–791. 36 indexed citations
13.
Nemunaitis, John, Michael Nemunaitis, Neil Senzer, et al.. (2009). Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Therapy. 16(8). 620–624. 116 indexed citations
14.
Nemunaitis, John, Robert O. Dillman, Paul Schwarzenberger, et al.. (2006). 1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC). Molecular Therapy. 13. S424–S425. 4 indexed citations
15.
Konduri, Kartik, Surinder S. Sahota, Gavin Babbage, et al.. (2005). Immunoglobulin M Myeloma: Evaluation of Molecular Features and Cytokine Expression. Clinical Lymphoma. 5(4). 285–289. 3 indexed citations
16.
Gonzalez, Melva L., et al.. (2004). Functional modulation of smooth muscle cells by the inflammatory mediator CAP37. Microvascular Research. 67(2). 168–181. 21 indexed citations
17.
Lee, Taunia D., Melva L. Gonzalez, Padmasini Kumar, Paula Grammas, & H. Anne Pereira. (2003). CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers. Microvascular Research. 66(1). 38–48. 48 indexed citations
18.
Lee, Taunia D., et al.. (2002). CAP37, a Novel Inflammatory Mediator. American Journal Of Pathology. 160(3). 841–848. 52 indexed citations
19.
Pereira, H. Anne, et al.. (2002). Activation of microglia: A neuroinflammatory role for CAP37. Glia. 41(1). 64–72. 34 indexed citations
20.
Pulendran, Bali, Padmasini Kumar, Christopher W. Cutler, et al.. (2001). Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo. The Journal of Immunology. 167(9). 5067–5076. 387 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Chang Breakdown of academic impact, for papers by Inbal Mishalian Breakdown of academic impact, for papers by Roberto Carrió Breakdown of academic impact, for papers by Mariette Mohaupt Breakdown of academic impact, for papers by Amanda Guth Breakdown of academic impact, for papers by Federica Pericle Breakdown of academic impact, for papers by Connor J. Dwyer Breakdown of academic impact, for papers by Lucia Schwarzfischer Breakdown of academic impact, for papers by Anthony Marinov Breakdown of academic impact, for papers by Masaaki Hashiguchi
Rankless by CCL
2026